---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000055"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:18:20.561683+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M

## Summary
- U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.
- Total revenue $164.9M incl. $40M milestone from CSL Vifor; net income $25.7M ($0.29 basic EPS) vs net loss of $54.8M in Q3 2024.
- Remaining $68.9M of 2025 convertible notes retired; cash & equivalents $254.5M as of Sep 30 (excl. October milestone).
- FDA sNDA for FILSPARI in FSGS under review; PDUFA target Jan 13, 2026; no advisory committee needed.
- REMS modified removing embryo-fetal toxicity monitoring; KDIGO guidelines recommend FILSPARI as first-line therapy in IgAN.

## SEC filing metadata
- accession: 0001438533-25-000055
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/0001438533-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/tvtx-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000055
- JSON: https://secwatch.observer/filing/0001438533-25-000055.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.